BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameBCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulators
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsLupus Erythematosus, SystemicPancytopeniaWaldenstrom Macroglobulinemia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesIcell Gene Therapeutics (Int'L) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesiCell Gene Therapeutics LLCiCar Bio Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicPancytopeniaWaldenstrom Macroglobulinemia +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A